Aster Capital Management’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$115 Buy
+1
New +$108 ﹤0.01% 940
2026
Q2
– Sell
-33
Closed -$3.77K – 924
2026
Q1
$3.77K Sell
33
-144
-81% -$5.38K ﹤0.01% 705
2025
Q4
$6.16K Buy
+177
New +$13.9K ﹤0.01% 836
2025
Q3
– Sell
-3,128
Closed -$230K – 1033
2025
Q2
$230K Buy
3,128
+1,334
+74% +$96.7K 0.05% 349
2025
Q1
$109K Buy
1,794
+1,750
+3,977% +$107K 0.02% 635
2024
Q4
$2.22K Buy
+44
New +$2.31K ﹤0.01% 961

Other funds holding CORT

Aster Capital Management's CORT Position: Q3 2026 in Review

Aster Capital Management opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 1 share worth $115. The stake represents ﹤0.01% of the portfolio and ranks #940 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in CORT as recently as Q1 2026.

Aster Capital Management first reported a position in CORT in Q4 2024 and has held it in 6 quarters since. The position peaked at $230K in Q2 2025. 503 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Aster Capital Management held 1 share of Corcept Therapeutics worth $115 as of Q3 2026.
  • Corcept Therapeutics was a new Aster Capital Management position in Q3 2026.
  • Corcept Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #940 holding.
  • Aster Capital Management first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Aster Capital Management's Corcept Therapeutics position peaked at $230K in Q2 2025.
  • 503 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.